Xianming Zhu

Xianming Zhu

Auto-generated profile, based on publicly available information

Xianming Zhu

Department of Pathology Johns Hopkins University School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2021 in Journal of Clinical Virology
Verified
Journal Article
Closed access
CHChristopher D. Heaney
Christopher D. Heaney
NPNora Pisanic
Nora Pisanic
PRPranay R. Randad
Pranay R. Randad
KKKate Kruczynski
Kate Kruczynski
THTyrone Howard
Tyrone Howard
ATAaron A.R. Tobian
Aaron A.R. Tobian

22 October 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
RGRuchika Goel
Ruchika Goel
XZXianming Zhu
Xianming Zhu
EPEshan Patel
Eshan Patel
ECElizabeth Patricia Crowe
Elizabeth Patricia Crowe
PNPaul M. Ness
Paul M. Ness
ATAaron A.R. Tobian
Aaron A.R. Tobian
Blood transfusions are among the most common therapeutic procedures performed in hospitalized patients. This study evaluates contemporary national trends in red blood cell (RBC), plasma, platelet, and cryoprecipitate transfusions. National Inpatient Sample, the largest all-payer inpatient database representing 94% to 97% of the US population, was evaluated from the fourth quarter (Q4) of 2015 through 2018. Quarterly trends for the percentage of hospitalizations with a transfusion procedure were separately examined for each blood product using log binomial regression and reported as quarterly percent change (QPC). The percentage of hospitalizations with an RBC transfusion decreased from 4.22% (2015Q4) to 3.79% (2018Q4) (QPC = −0.72; 95% confidence interval [CI], −1.26 to −0.19; Ptrend = .008). Although plasma transfusions also decreased, QPC = −1.33 (95% CI, −2.00 to −0.65; Ptrend < .001), platelet transfusions remained stable QPC = −0.13 (95% CI, −0.99 to 0.73; Ptrend = .766). In contrast, hospitalizations with cryoprecipitate utilization significantly increased QPC = 2.01 (95% CI, 0.57 to 3.44; Ptrend = .006). Significant quarterly reductions in RBC transfusions were also seen among many, but not all, strata of sex, race/ethnicity, patient risk severity, and admission type (elective vs nonelective). Despite significant declines in RBC transfusions among older adults, there were no significant changes among pediatric age-group (<18 years) and those 18 to 49 years. The decline in RBC and plasma transfusions suggests steady incorporation of robust evidence base showing safety of restrictive transfusions. Increased cryoprecipitate use may be reflective of wider adoption of hypofibrinogenemia management and hemostasis testing for coagulopathic patients.

31 October 2023 in mBio
Verified
Journal Article
Closed access
KGKelly A. Gebo
Kelly A. Gebo
SHSonya L. Heath
Sonya L. Heath
YFYuriko Fukuta
Yuriko Fukuta
XZXianming Zhu
Xianming Zhu
SBSheriza Baksh
Sheriza Baksh
DSDavid Sullivan
David Sullivan
Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of COVID-19 convalescent plasma (CCP) vs control plasma with available biospecimens and symptom data, the association between early CCP treatment, cytokine levels, and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14, and day 90 using a multiplexed sandwich immunoassay (Meso Scale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between CCP treatment, cytokine levels, and PCC were examined using multivariate logistic regression models. One third of the 882 participants had day 90 PCC symptoms, with fatigue (14.5%) and anosmia (14.5%) being most common. Cytokine levels decreased from baseline to day 90. In a multivariable analysis, female sex (adjusted odds ratio [AOR] = 2.69 [1.93–3.81]), older age (AOR = 1.32 [1.17–1.50]), and elevated baseline levels of IL-6 (AOR = 1.59 [1.02–2.47]) were independently associated with development of PCC. Those who received early CCP treatment (≤5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC. IMPORTANCE: Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.

8 November 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
SBSarah E. Benner
Sarah E. Benner
YEYolanda Eby
Yolanda Eby
XZXianming Zhu
Xianming Zhu
RFReinaldo E. Fernandez
Reinaldo E. Fernandez
EPEshan Patel
Eshan Patel
ATAaron A.R. Tobian
Aaron A.R. Tobian
The HIV latent viral reservoir (LVR) remains a major challenge in the effort to find a cure for HIV. There is interest in lymphocyte-depleting agents, used in solid organ and bone marrow transplantation to reduce the LVR. This study evaluated the LVR and T cell receptor repertoire in HIV-infected kidney transplant recipients using intact proviral DNA assay and T cell receptor sequencing in patients receiving lymphocyte-depleting or lymphocyte-nondepleting immunosuppression induction therapy. CD4 + T cells and intact and defective provirus frequencies decreased following lymphocyte-depleting induction therapy but rebounded to near baseline levels within 1 year after induction. In contrast, these biomarkers were relatively stable over time in the lymphocyte-nondepleting group. The lymphocyte-depleting group had early TCRβ repertoire turnover and newly detected and expanded clones compared with the lymphocyte-nondepleting group. No differences were observed in TCRβ clonality and repertoire richness between groups. These findings suggest that, even with significant decreases in the overall size of the circulating LVR, the reservoir can be reconstituted in a relatively short period of time. These results, while from a relatively unique population, suggest that curative strategies aimed at depleting the HIV LVR will need to achieve specific and durable levels of HIV-infected T cell depletion.

2 July 2021 in Transfusion
Verified
Journal Article
Closed access
PDF file
RGRuchika Goel
Ruchika Goel
XZXianming Zhu
Xianming Zhu
SMSarah Makhani
Sarah Makhani
MPMolly R. Petersen
Molly R. Petersen
CJCassandra D. Josephson
Cassandra D. Josephson
ATAaron A. R. Tobian
Aaron A. R. Tobian

18 November 2021 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
RKRobert L. Kruse
Robert L. Kruse
YHYuting Huang
Yuting Huang
ALAlyssa Lee
Alyssa Lee
XZXianming Zhu
Xianming Zhu
RSRuchee Shrestha
Ruchee Shrestha
ZWZack Wang
Zack Wang
Serologic point-of-care tests to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are an important tool in the COVID-19 pandemic. The majority of current point-of-care antibody tests developed for SARS-CoV-2 rely on lateral flow assays, but these do not offer quantitative information.